The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus.
Donath
Marc Y
MY
Clinic for Endocrinology and Diabetes, University Hospital Zurich and Center for Integrated Human Physiology, University of Zurich, Switzerland.
Mandrup-Poulsen
Thomas
T
D054392:Adipokines / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage*; D015850:Interleukin-6 / Q000097:blood; D011384:Proinsulin / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*
D054392:Adipokines; D002097:C-Reactive Protein; D006442:Glycated Hemoglobin; D007328:Insulin; D053590:Interleukin 1 Receptor Antagonist Protein; D015850:Interleukin-6; D011384:Proinsulin; D017472:Receptors, Interleukin-1